Actavis Now Covered by RBC Capital (ACT)
Stock analysts at RBC Capital began coverage on shares of Actavis (NYSE:ACT) in a report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $202.00 price target on the stock. RBC Capital’s price target indicates a potential upside of 18.89% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks downgraded shares of Actavis from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, November 28th. They now have a $172.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Actavis from $155.00 to $186.00 in a research note to investors on Wednesday, October 30th. They now have a “buy” rating on the stock. Finally, analysts at Susquehanna raised their price target on shares of Actavis from $165.00 to $170.00 in a research note to investors on Wednesday, October 30th. They now have a “neutral” rating on the stock. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $157.61.
Shares of Actavis (NYSE:ACT) traded up 1.17% on Tuesday, hitting $169.90. The stock had a trading volume of 1,188,998 shares. Actavis has a 52-week low of $82.02 and a 52-week high of $172.49. The stock has a 50-day moving average of $163.9 and a 200-day moving average of $144.6. The company’s market cap is $29.563 billion.
Actavis (NYSE:ACT) last announced its earnings results on Tuesday, October 29th. The company reported $2.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.09. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $2.04 billion. The company’s revenue for the quarter was up 56.7% on a year-over-year basis. Analysts expect that Actavis will post $9.34 EPS for the current fiscal year.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.